+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Drugs Used for Treating Primary Aldosteronism Market - Global Forecast to 2030- Product Image
Drugs Used for Treating Primary Aldosteronism Market - Global Forecast to 2030- Product Image
New

Drugs Used for Treating Primary Aldosteronism Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 196 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6081445
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Primary aldosteronism, characterized by the excessive secretion of aldosterone by the adrenal glands, has emerged as a critical contributor to secondary hypertension and cardiovascular morbidity. Over the past decade, advances in our understanding of the disease’s pathophysiology have spurred the development of novel therapeutic classes and refined clinical pathways. As clinicians seek to balance efficacy, safety and patient adherence, the treatment landscape has grown increasingly complex. This executive summary offers an in-depth overview of current drug modalities, recent shifts in market dynamics, the projected effects of pending United States tariffs, detailed segmentation analyses, regional trends and key corporate activities. By synthesizing these insights, decision-makers can better navigate opportunities, anticipate challenges and shape strategic initiatives to optimize patient outcomes in primary aldosteronism management.

Transformative Shifts Reshaping Treatment Strategies

The treatment paradigm for primary aldosteronism has undergone transformative shifts driven by targeted molecule innovation, regulatory milestones and evolving clinical guidelines. First, the introduction of aldosterone synthase inhibitors has expanded options beyond traditional mineralocorticoid receptor antagonists, offering a mechanism-based approach that directly suppresses hormone overproduction. Simultaneously, refinements in diagnostic protocols-including adrenal venous sampling and advanced imaging-have enabled earlier detection and patient stratification, directing therapy toward unilateral or bilateral disease phenotypes. Moreover, digital health tools and patient compliance devices are increasingly embedded into care pathways, allowing real-time monitoring of blood pressure and adherence, which in turn supports personalized dosing and follow-up schedules. Lastly, as precision medicine initiatives gain momentum, companion diagnostics such as biomarker panels and genetic testing are guiding therapeutic selection, ensuring that antihypertensives, diuretics or hormonal therapies align with individual patient profiles. Together, these developments have recalibrated clinical decision making, reduced adverse events and bolstered long-term disease control.

Assessing the 2025 United States Tariffs Impact on Drug Supply

In early 2025, the United States enacted a new set of tariffs aimed at medical imports to rebalance trade deficits and support domestic pharmaceutical manufacturing. These measures have increased duties on active pharmaceutical ingredients and specialty drug formulations, driving adjustments across the supply chain. Manufacturers are responding by relocating key production steps to onshore facilities or nearshore partners, which has accelerated capital investment in U.S. plant expansions and quality control infrastructure. However, those changes have also led to transitional cost pressures, prompting healthcare providers and payers to renegotiate contracts and reassess formularies. Drug pricing committees are factoring in tariff-induced cost variability when evaluating treatment affordability, particularly for high-value branded agents such as novel aldosterone synthase inhibitors. Meanwhile, logistics providers are diversifying transport routes to avoid tariff zones, leveraging free trade agreement corridors with Canada and Mexico. From a market access standpoint, early engagement with regulatory authorities and transparent cost-sharing frameworks have mitigated potential disruptions for patients reliant on chronic therapies. These strategic adaptations underscore the sector’s resilience and ability to maintain continuity of care under shifting trade policies.

Key Segmentation Insights Across Multiple Dimensions

A comprehensive segmentation framework reveals nuanced performance drivers and unmet needs across multiple dimensions. When parsing the market by drug type-including aldosterone synthase inhibitors, angiotensin-converting enzyme inhibitors, calcium channel blockers, mineralocorticoid receptor antagonists and potassium-sparing diuretics-it becomes evident that each class addresses different facets of pathophysiology, from direct hormone suppression to vascular tone modulation. Segmenting patients by age group into adult cohorts-young, middle-aged and senior adults-and pediatric populations highlights growing interest in age-specific safety data and dose optimization studies, especially as therapy penetrates mature and underserved segments. The mode of administration dimension, spanning injectable routes such as intravenous and subcutaneous, oral formulations in capsule and tablet forms, and topical options, underscores shifts toward patient convenience and adherence. In the therapeutic class segmentation, antihypertensives remain dominant, but hormonal therapies and diuretics are gaining traction as combination regimens. End-user analysis across ambulatory surgical centers, homecare settings, hospitals and specialty clinics sheds light on evolving care delivery models, where decentralized treatment and remote monitoring are on the rise. Patient compliance device segmentation-from electronic adherence monitors and medication organizers to smart pills with embedded sensors and telemedicine platforms-illustrates the convergence of hardware and software in chronic disease management. Exploring drug availability channels, including online pharmacies, over-the-counter options and prescription-based pathways, reveals shifting patient preferences and regulatory adaptations. Development stage insights-from preclinical trials through Phases I to III, FDA approval and post-market surveillance-highlight bottlenecks and acceleration points in bringing novel agents to market. Brand versus generic distinctions underscore cost-containment pressures versus patient trust in established formulations. Patient support program segmentation-encompassing cost assistance, disease management services and loyalty initiatives-emphasizes the importance of holistic care models. Finally, companion diagnostics such as biomarker identification, clinical decision support systems and genetic testing are central to precision treatment algorithms, ensuring that each intervention aligns with molecular and clinical markers.

Regional Dynamics Driving Market Trends Globally

Regional dynamics are shaping the competitive and regulatory environment in distinct ways. In the Americas, advanced healthcare infrastructure and reimbursement frameworks facilitate early adoption of novel therapeutics, yet pricing scrutiny by public and private payers demands robust pharmacoeconomic evidence. Latin American markets are emerging as high-growth pockets, with governments incentivizing local production to improve access. Europe, the Middle East and Africa present a heterogeneous landscape: Western Europe benefits from coordinated health technology assessments, while Central and Eastern European countries prioritize generics and cost-effective therapies. In the Gulf Cooperation Council states, rising prevalence of hypertension has spurred investment in specialty clinics and digital health platforms. Africa’s market remains fragmented, with ongoing efforts to strengthen regulatory harmonization and supply chain resilience. Asia-Pacific exhibits dual dynamics: mature markets like Japan and Australia emphasize innovation and regulatory rigor, contrasted with emerging economies in Southeast Asia and South Asia where affordability and generic penetration drive volume growth. Across all regions, cross-border collaborations and public-private partnerships are accelerating clinical trial enrollment and expanding patient access to state-of-the-art therapies.

Competitive Landscape and Leading Company Strategies

The competitive landscape is defined by a mix of global pharmaceutical giants, regionally focused players and innovative biotechs. AbbVie Inc. has leveraged its cardiovascular franchise to explore combination regimens, while Aspen Pharmacare Holdings Limited focuses on generic mineralocorticoid receptor antagonists tailored for cost-sensitive markets. Bayer AG continues to invest in aldosterone synthase inhibitor pipelines, building on its research in endocrine disorders. Bristol-Myers Squibb Company emphasizes immunomodulatory approaches that may complement hormonal regulation. Cipla Limited harnesses its low-cost manufacturing capabilities to broaden access to ACE inhibitors and diuretics. Daiichi Sankyo Company, Limited is advancing subcutaneous formulations for improved patient adherence. Hikma Pharmaceuticals PLC, Lupin Pharmaceuticals, Inc. and Sun Pharmaceutical Industries Ltd. are scaling production of generic capsules and tablets in emerging regions, while Merck & Co., Inc., Novartis AG and Pfizer Inc. spearhead next-generation molecule discovery and digital health integration. Sanofi S.A. is piloting telemedicine-driven care models, and Teva Pharmaceutical Industries Ltd. continues to expand its specialty clinic partnerships for hormone therapies. Zydus Cadila Healthcare Limited rounds out the field with precision dosing studies and companion diagnostic collaborations. Collectively, these companies are harnessing differentiated portfolios, strategic alliances and R&D investments to capture growth opportunities and address treatment gaps in primary aldosteronism management.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize a multi-pronged approach to sustain growth and address evolving patient needs. First, integrating companion diagnostics into clinical workflows will refine patient selection and accelerate time to therapeutic benefit, reducing trial-and-error prescribing. Second, expanding remote monitoring and digital adherence technologies-such as smart pill sensors and telemedicine platforms-can enhance real-world data collection, bolster compliance and support value-based contracting with payers. Third, companies must diversify manufacturing footprints to mitigate tariff impacts and supply chain disruptions, balancing cost efficiency with regional resilience. Fourth, collaborative engagements with regulatory authorities and health authorities can streamline approval pathways for novel drug classes, particularly aldosterone synthase inhibitors and innovative hormone therapies. Fifth, forging partnerships with specialty clinics, homecare providers and surgical centers will embed therapies within comprehensive care models, improving patient convenience and outcomes. Finally, implementing tiered pricing strategies and patient support programs-spanning cost assistance, disease management and loyalty incentives-will expand access in both mature and emerging markets while safeguarding profitability.

Conclusion: Navigating Future Opportunities in Treatment

As the landscape of primary aldosteronism treatment continues to evolve, stakeholders must remain agile and patient-centric. The convergence of targeted therapeutics, advanced diagnostics and digital health tools presents unprecedented opportunities to enhance efficacy and adherence. Trade policy shifts and tariff adjustments underscore the need for supply chain resilience and cost transparency. Meanwhile, regional disparities in access and infrastructure call for tailored market entry and commercialization strategies. By embracing precision medicine principles, fostering cross-sector collaboration and investing in data-driven care delivery, organizations can drive sustainable growth and improve life-long outcomes for patients living with primary aldosteronism.

Market Segmentation & Coverage

This research report categorizes the Drugs Used for Treating Primary Aldosteronism Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Aldosterone Synthase Inhibitors
  • Angiotensin-Converting Enzyme (ACE) Inhibitors
  • Calcium Channel Blockers
  • Mineralocorticoid Receptor Antagonists
  • Potassium-Sparing Diuretics
  • Adult
    • Middle-Aged Adults
    • Senior Adults
    • Young Adults
  • Pediatric
  • Injectable
    • Intravenous
    • Subcutaneous
  • Oral
    • Capsule
    • Tablet
  • Topical
  • Antihypertensives
  • Diuretics
  • Hormonal Therapy
  • Ambulatory Surgical Centers
  • Homecare Settings
  • Hospitals
  • Specialty Clinics
  • Electronic Adherence Monitors
  • Medication Organizers
  • Smart Pills
    • Sensors for Monitoring
  • Telemedicine Platforms
  • Online Pharmacies
  • Over-The-Counter
  • Prescription-Based
  • FDA Approval
  • Phase I Clinical Trials
  • Phase II Clinical Trials
  • Phase III Clinical Trials
  • Post-Market Surveillance
  • Preclinical Trials
  • Brand-Name Drugs
  • Generic Drugs
  • Cost Assistance Programs
  • Disease Management
  • Loyalty Programs
  • Biomarker Identification
  • Clinical Decision Support Systems
  • Genetic Testing

This research report categorizes the Drugs Used for Treating Primary Aldosteronism Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Drugs Used for Treating Primary Aldosteronism Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • Aspen Pharmacare Holdings Limited
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Daiichi Sankyo Company, Limited
  • Hikma Pharmaceuticals PLC
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila Healthcare Limited

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Drugs Used for Treating Primary Aldosteronism Market, by Drug Type
8.1. Introduction
8.2. Aldosterone Synthase Inhibitors
8.3. Angiotensin-Converting Enzyme (ACE) Inhibitors
8.4. Calcium Channel Blockers
8.5. Mineralocorticoid Receptor Antagonists
8.6. Potassium-Sparing Diuretics
9. Drugs Used for Treating Primary Aldosteronism Market, by Age Group
9.1. Introduction
9.2. Adult
9.2.1. Middle-Aged Adults
9.2.2. Senior Adults
9.2.3. Young Adults
9.3. Pediatric
10. Drugs Used for Treating Primary Aldosteronism Market, by Mode Of Administration
10.1. Introduction
10.2. Injectable
10.2.1. Intravenous
10.2.2. Subcutaneous
10.3. Oral
10.3.1. Capsule
10.3.2. Tablet
10.4. Topical
11. Drugs Used for Treating Primary Aldosteronism Market, by Therapeutic Class
11.1. Introduction
11.2. Antihypertensives
11.3. Diuretics
11.4. Hormonal Therapy
12. Drugs Used for Treating Primary Aldosteronism Market, by End-User
12.1. Introduction
12.2. Ambulatory Surgical Centers
12.3. Homecare Settings
12.4. Hospitals
12.5. Specialty Clinics
13. Drugs Used for Treating Primary Aldosteronism Market, by Patient Compliance Device
13.1. Introduction
13.2. Electronic Adherence Monitors
13.3. Medication Organizers
13.4. Smart Pills
13.4.1. Sensors for Monitoring
13.5. Telemedicine Platforms
14. Drugs Used for Treating Primary Aldosteronism Market, by Drug Availability
14.1. Introduction
14.2. Online Pharmacies
14.3. Over-The-Counter
14.4. Prescription-Based
15. Drugs Used for Treating Primary Aldosteronism Market, by Development Stage
15.1. Introduction
15.2. FDA Approval
15.3. Phase I Clinical Trials
15.4. Phase II Clinical Trials
15.5. Phase III Clinical Trials
15.6. Post-Market Surveillance
15.7. Preclinical Trials
16. Drugs Used for Treating Primary Aldosteronism Market, by Brand Vs. Generic
16.1. Introduction
16.2. Brand-Name Drugs
16.3. Generic Drugs
17. Drugs Used for Treating Primary Aldosteronism Market, by Patient Support Programs
17.1. Introduction
17.2. Cost Assistance Programs
17.3. Disease Management
17.4. Loyalty Programs
18. Drugs Used for Treating Primary Aldosteronism Market, by Companion Diagnostics
18.1. Introduction
18.2. Biomarker Identification
18.3. Clinical Decision Support Systems
18.4. Genetic Testing
19. Americas Drugs Used for Treating Primary Aldosteronism Market
19.1. Introduction
19.2. Argentina
19.3. Brazil
19.4. Canada
19.5. Mexico
19.6. United States
20. Asia-Pacific Drugs Used for Treating Primary Aldosteronism Market
20.1. Introduction
20.2. Australia
20.3. China
20.4. India
20.5. Indonesia
20.6. Japan
20.7. Malaysia
20.8. Philippines
20.9. Singapore
20.10. South Korea
20.11. Taiwan
20.12. Thailand
20.13. Vietnam
21. Europe, Middle East & Africa Drugs Used for Treating Primary Aldosteronism Market
21.1. Introduction
21.2. Denmark
21.3. Egypt
21.4. Finland
21.5. France
21.6. Germany
21.7. Israel
21.8. Italy
21.9. Netherlands
21.10. Nigeria
21.11. Norway
21.12. Poland
21.13. Qatar
21.14. Russia
21.15. Saudi Arabia
21.16. South Africa
21.17. Spain
21.18. Sweden
21.19. Switzerland
21.20. Turkey
21.21. United Arab Emirates
21.22. United Kingdom
22. Competitive Landscape
22.1. Market Share Analysis, 2024
22.2. FPNV Positioning Matrix, 2024
22.3. Competitive Analysis
22.3.1. AbbVie Inc.
22.3.2. Aspen Pharmacare Holdings Limited
22.3.3. Bayer AG
22.3.4. Bristol-Myers Squibb Company
22.3.5. Cipla Limited
22.3.6. Daiichi Sankyo Company, Limited
22.3.7. Hikma Pharmaceuticals PLC
22.3.8. Lupin Pharmaceuticals, Inc.
22.3.9. Merck & Co., Inc.
22.3.10. Novartis AG
22.3.11. Pfizer Inc.
22.3.12. Sanofi S.A.
22.3.13. Sun Pharmaceutical Industries Ltd.
22.3.14. Teva Pharmaceutical Industries Ltd.
22.3.15. Zydus Cadila Healthcare Limited
23. ResearchAI
24. ResearchStatistics
25. ResearchContacts
26. ResearchArticles
27. Appendix
List of Figures
FIGURE 1. DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET MULTI-CURRENCY
FIGURE 2. DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET MULTI-LANGUAGE
FIGURE 3. DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT COMPLIANCE DEVICE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT COMPLIANCE DEVICE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG AVAILABILITY, 2024 VS 2030 (%)
FIGURE 20. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG AVAILABILITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2030 (%)
FIGURE 22. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY BRAND VS. GENERIC, 2024 VS 2030 (%)
FIGURE 24. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY BRAND VS. GENERIC, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT SUPPORT PROGRAMS, 2024 VS 2030 (%)
FIGURE 26. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT SUPPORT PROGRAMS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COMPANION DIAGNOSTICS, 2024 VS 2030 (%)
FIGURE 28. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COMPANION DIAGNOSTICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 32. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 34. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 35. EUROPE, MIDDLE EAST & AFRICA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 36. EUROPE, MIDDLE EAST & AFRICA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 37. DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 38. DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ALDOSTERONE SYNTHASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MINERALOCORTICOID RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY POTASSIUM-SPARING DIURETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MIDDLE-AGED ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY SENIOR ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY YOUNG ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ANTIHYPERTENSIVES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT COMPLIANCE DEVICE, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ELECTRONIC ADHERENCE MONITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MEDICATION ORGANIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY SMART PILLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY SENSORS FOR MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY SMART PILLS, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY TELEMEDICINE PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG AVAILABILITY, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY OVER-THE-COUNTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PRESCRIPTION-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY FDA APPROVAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PHASE I CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PHASE II CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY POST-MARKET SURVEILLANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PRECLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY BRAND VS. GENERIC, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY BRAND-NAME DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT SUPPORT PROGRAMS, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COST ASSISTANCE PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DISEASE MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY LOYALTY PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY BIOMARKER IDENTIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY CLINICAL DECISION SUPPORT SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT COMPLIANCE DEVICE, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY SMART PILLS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG AVAILABILITY, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY BRAND VS. GENERIC, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT SUPPORT PROGRAMS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT COMPLIANCE DEVICE, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY SMART PILLS, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG AVAILABILITY, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY BRAND VS. GENERIC, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT SUPPORT PROGRAMS, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT COMPLIANCE DEVICE, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY SMART PILLS, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG AVAILABILITY, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY BRAND VS. GENERIC, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT SUPPORT PROGRAMS, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 113. CANADA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 114. CANADA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 115. CANADA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 116. CANADA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. CANADA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 118. CANADA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 119. CANADA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 120. CANADA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. CANADA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT COMPLIANCE DEVICE, 2018-2030 (USD MILLION)
TABLE 122. CANADA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY SMART PILLS, 2018-2030 (USD MILLION)
TABLE 123. CANADA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG AVAILABILITY, 2018-2030 (USD MILLION)
TABLE 124. CANADA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 125. CANADA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY BRAND VS. GENERIC, 2018-2030 (USD MILLION)
TABLE 126. CANADA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT SUPPORT PROGRAMS, 2018-2030 (USD MILLION)
TABLE 127. CANADA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 128. MEXICO DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 129. MEXICO DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 130. MEXICO DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 131. MEXICO DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. MEXICO DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 133. MEXICO DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 134. MEXICO DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 135. MEXICO DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. MEXICO DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT COMPLIANCE DEVICE, 2018-2030 (USD MILLION)
TABLE 137. MEXICO DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY SMART PILLS, 2018-2030 (USD MILLION)
TABLE 138. MEXICO DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG AVAILABILITY, 2018-2030 (USD MILLION)
TABLE 139. MEXICO DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 140. MEXICO DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY BRAND VS. GENERIC, 2018-2030 (USD MILLION)
TABLE 141. MEXICO DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT SUPPORT PROGRAMS, 2018-2030 (USD MILLION)
TABLE 142. MEXICO DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 143. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 144. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 145. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 146. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 147. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 148. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 149. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 150. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 151. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT COMPLIANCE DEVICE, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY SMART PILLS, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG AVAILABILITY, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY BRAND VS. GENERIC, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT SUPPORT PROGRAMS, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 159. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 160. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 161. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 162. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 164. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 165. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 166. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 167. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT COMPLIANCE DEVICE, 2018-2030 (USD MILLION)
TABLE 168. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY SMART PILLS, 2018-2030 (USD MILLION)
TABLE 169. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG AVAILABILITY, 2018-2030 (USD MILLION)
TABLE 170. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY BRAND VS. GENERIC, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT SUPPORT PROGRAMS, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 175. AUSTRALIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 176. AUSTRALIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 177. AUSTRALIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 178. AUSTRALIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. AUSTRALIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 180. AUSTRALIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 181. AUSTRALIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 182. AUSTRALIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 183. AUSTRALIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT COMPLIANCE DEVICE, 2018-2030 (USD MILLION)
TABLE 184. AUSTRALIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY SMART PILLS, 2018-2030 (USD MILLION)
TABLE 185. AUSTRALIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG AVAILABILITY, 2018-2030 (USD MILLION)
TABLE 186. AUSTRALIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 187. AUSTRALIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY BRAND VS. GENERIC, 2018-2030 (USD MILLION)
TABLE 188. AUSTRALIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT SUPPORT PROGRAMS, 2018-2030 (USD MILLION)
TABLE 189. AUSTRALIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 190. CHINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 191. CHINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 192. CHINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 193. CHINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 194. CHINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 195. CHINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 196. CHINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 197. CHINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 198. CHINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT COMPLIANCE DEVICE, 2018-2030 (USD MILLION)
TABLE 199. CHINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY SMART PILLS, 2018-2030 (USD MILLION)
TABLE 200. CHINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG AVAILABILITY, 2018-2030 (USD MILLION)
TABLE 201. CHINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 202. CHINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY BRAND VS. GENERIC, 2018-2030 (USD MILLION)
TABLE 203. CHINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT SUPPORT PROGRAMS, 2018-2030 (USD MILLION)
TABLE 204. CHINA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 205. INDIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 206. INDIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 207. INDIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 208. INDIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. INDIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 210. INDIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 211. INDIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 212. INDIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 213. INDIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT COMPLIANCE DEVICE, 2018-2030 (USD MILLION)
TABLE 214. INDIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY SMART PILLS, 2018-2030 (USD MILLION)
TABLE 215. INDIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG AVAILABILITY, 2018-2030 (USD MILLION)
TABLE 216. INDIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 217. INDIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY BRAND VS. GENERIC, 2018-2030 (USD MILLION)
TABLE 218. INDIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT SUPPORT PROGRAMS, 2018-2030 (USD MILLION)
TABLE 219. INDIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 220. INDONESIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 221. INDONESIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 222. INDONESIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 223. INDONESIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 224. INDONESIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 225. INDONESIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 226. INDONESIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 227. INDONESIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 228. INDONESIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT COMPLIANCE DEVICE, 2018-2030 (USD MILLION)
TABLE 229. INDONESIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY SMART PILLS, 2018-2030 (USD MILLION)
TABLE 230. INDONESIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG AVAILABILITY, 2018-2030 (USD MILLION)
TABLE 231. INDONESIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 232. INDONESIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY BRAND VS. GENERIC, 2018-2030 (USD MILLION)
TABLE 233. INDONESIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT SUPPORT PROGRAMS, 2018-2030 (USD MILLION)
TABLE 234. INDONESIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 235. JAPAN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 236. JAPAN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 237. JAPAN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 238. JAPAN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. JAPAN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 240. JAPAN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 241. JAPAN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 242. JAPAN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 243. JAPAN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT COMPLIANCE DEVICE, 2018-2030 (USD MILLION)
TABLE 244. JAPAN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY SMART PILLS, 2018-2030 (USD MILLION)
TABLE 245. JAPAN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG AVAILABILITY, 2018-2030 (USD MILLION)
TABLE 246. JAPAN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 247. JAPAN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY BRAND VS. GENERIC, 2018-2030 (USD MILLION)
TABLE 248. JAPAN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT SUPPORT PROGRAMS, 2018-2030 (USD MILLION)
TABLE 249. JAPAN DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 250. MALAYSIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 251. MALAYSIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 252. MALAYSIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ADULT, 2018-2030 (USD MILLION)
TABLE 253. MALAYSIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 254. MALAYSIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 255. MALAYSIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 256. MALAYSIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 257. MALAYSIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 258. MALAYSIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT COMPLIANCE DEVICE, 2018-2030 (USD MILLION)
TABLE 259. MALAYSIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY SMART PILLS, 2018-2030 (USD MILLION)
TABLE 260. MALAYSIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG AVAILABILITY, 2018-2030 (USD MILLION)
TABLE 261. MALAYSIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 262. MALAYSIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY BRAND VS. GENERIC, 2018-2030 (USD MILLION)
TABLE 263. MALAYSIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY PATIENT SUPPORT PROGRAMS, 2018-2030 (USD MILLION)
TABLE 264. MALAYSIA DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY COMPANION DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 265. PHILIPPINES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 266. PHILIPPINES DRUGS USED FOR TREATING PRIMARY ALDOSTERONISM MARKET SIZE, BY A

Companies Mentioned

  • AbbVie Inc.
  • Aspen Pharmacare Holdings Limited
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Daiichi Sankyo Company, Limited
  • Hikma Pharmaceuticals PLC
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila Healthcare Limited

Methodology

Loading
LOADING...

Related Topics

Related Reports

Aldosterone Synthase Inhibitors - Pipeline Insight, 2025 - Product Image

Aldosterone Synthase Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Drugs for Treating Hyperuricemia Market - Global Forecast to 2030 - Product Image

Drugs for Treating Hyperuricemia Market - Global Forecast to 2030

  • Report
  • 189 Pages
  • Global
From
Treating Chronic Myeloid Leukemia by Phase Market - Global Forecast to 2030 - Product Image

Treating Chronic Myeloid Leukemia by Phase Market - Global Forecast to 2030

  • Report
  • 184 Pages
  • Global
From
Immune Thrombocytopenia Market Insights, Epidemiology, and Market Forecast - 2034 - Product Image

Immune Thrombocytopenia Market Insights, Epidemiology, and Market Forecast - 2034

  • Report
  • 207 Pages
  • Global
From
Topical Drugs Market Size, Share & Trends Analysis Report By Route Of Administration, By Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Topical Drugs Market Size, Share & Trends Analysis Report By Route Of Administration, By Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.